Significant Research from the Forsyth Institute Explains Why Popular Antacids May Increase Chance of Bone Fractures
Newly published research from the Forsyth Institute details a discovery explaining why the 100 million Americans estimated to be taking prescription and over-the-counter (OTC) antacid and heartburn medications may be at an increased risk of bone fractures.
The new report from Forsyth, published in the March issue of PLOS Genetics, explains that stomach acid in the gastrointestinal tract plays an important role in helping the intestines absorb and transfer calcium to the skeletal system. While the introduction of proton pump inhibitor-based antacids reduces the level of acidity in the stomach to bring relief to patients, the reduction also interrupts and even stops the gut from absorbing much needed calcium.
The connection between proton pump inhibitors and bone fractures has been well established, with the FDA in 2010 requiring a warning label placed on all product packaging. Other research has indicated these medications may block the absorption of important nutrients, but until this study it was not known how or why this was happening in the body.
“The regulation of bone mass by the gastrointestinal tract represents a remarkable example of an unexpected and important relationship between these two systems that is only now becoming fully appreciated,” said Dr Ricardo Battaglino of the Forsyth Institute. “It could help us better understand and find new ways to treat common clinical conditions that currently require medications which have been linked to weakened bones, such as popular antacids.”
OTC and prescription antacids are used by 100 million Americans to treat heartburn and related conditions. It is the third highest selling drug category with $14 billion in annual sales according to the American Academy of Family Physicians. Fractures at the hip, wrist, arm, ribs and even vertebrae – especially in individuals aged 50 and older — can permanently impair quality of life and result in an expensive drain on the American healthcare system.
Related News
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News A Day in the Life of a Vice President in R&D & Engineering
In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance